This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Adding the targeted radioactive drug 177Lu-PNT2002 to stereotactic body radiation therapy, or SBRT, may help keep recurrent prostate cancer under control longer than SBRT alone, according to new research led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
The team found patients who received the combination were less likely to develop widespread disease or hormone-resistant cancer, suggesting the treatment may offer benefits beyond delaying the initial return of the disease.
The findings, published in the journal European Urology, come from an updated analysis of the phase 2 LUNAR trial, which followed men for nearly three years after their prostate cancer had returned and was detected in a limited number of sites.
"Our earlier findings showed that adding 177Lu-PNT2002 could significantly delay progression and the need for hormone therapy," said Dr. Amar Kishan, executive vice chair of radiation oncology at the David Geffen School of Medicine at UCLA and first author of the study.
"But with longer follow-up, we're seeing signs that the benefit may extend beyond simply delaying recurrence, including a potential reduction in the risk of widespread disease and cancer that no longer responds to hormone therapy.
Source link
